Eye drops and similar formulations are washed away with blinking, so on average less than five percent of the drug reaches its target tissue.
“Total drug delivered using this hydrogel nanoparticle formulation was three-times higher than the standard control formulation,” according to a release.
InMed, a biopharmeceutical company, describes its proprietary hydrogel delivery method as having “unique rheological characteristics permitting it to form a thin, uniform coating (a gel-like lens) over the cornea through blinking of the eyelid. This lens holds the drug in place and allows for trans-corneal absorption of the drug, which can then diffuse within the eye to the retina.”
Eric A. Adams, InMed president and CEO, said
“This study offers the first tangible proof of our ability to successfully identify specific drug targets using our bioinformatic assessment tools, manufacture a cannabinoid using our proprietary biosynthesis process, load the drug into a patented, target specific formulation and deliver effective dose levels to a target tissue.”
This company-sponsored research study was recently published in the peer reviewed Journal of Controlled Release (JCR), entitled “A stimulus-responsive, in situ forming, nanoparticle-laden hydrogel for ocular drug delivery.”
READ FULL ARTICLE AT CASHINBIS
Read More